Electronic cigarettes containing nicotine can double smokers' rates of quitting at one year, compared to e-cigarettes without nicotine (placebo), according to a new small meta-analysis published in the Cochrane Database of Systematic Reviews. The rates of smoking cessation using nicotine-containing e-cigarettes (9%) were roughly comparable to that seen with other forms of nicotine replacement therapy in past trials. The [... read more]
The post E-cigarettes double smokers’ quit rates vs placebo: meta-analysis appeared first on PulmCCM.
The American College of Radiology has started implementing its new system for risk-stratifying the findings on low dose chest CTs performed for lung cancer screening. The ACR's new system is called Lung-RADS™, and it emulates the ACR's familiar Bi-RADS's 0-4 scoring system for mammography: Lung-RADS 0: Incomplete, meaning previous chest CTs are still being located [... read more]
The post Lung-RADS launches: New system for lung cancer screening chest CTs appeared first on PulmCCM.
image: Olympus Most lung cancers spread to the lymph nodes in the chest first. Unless distant spread to other organs (metastasis) is obvious, biopsy of any suspicious intrathoracic lymph nodes is necessary to stage and prognose lung cancer. The presence or absence of cancerous lymph nodes, and their location in relation to the lung cancer, determine [... read more]
The post Who needs mediastinoscopy after negative EBUS staging for lung cancer? appeared first on PulmCCM.
“Set a quit date to stop smoking,” goes the old bit of doctor’s advice. Experts argue people need to psyche themselves up, get serious, commit to quitting before the last butt goes in the ashtray. A new study in JAMA suggests that advice may be outdated. Smokers unready to quit who took the cessation drug varenicline (Chantix) for several months, [... read more]
The post Chantix works even if you’re just thinking of quitting smoking appeared first on PulmCCM.
Longtime readers of PulmCCM will remember, there once was an app for iPhone and Android phones. Then, one day, there wasn't. Technical difficulties, etc. Then, just when everyone had almost forgotten about it, the app was back! Most people had moved on with their lives, but a few were touched by this digital comeback story. Then -- [... read more]
The post The PulmCCM App Re-Re-Launches, Again appeared first on PulmCCM.
The U.S. FDA continued its flurry of new antibiotic approvals to close out 2014, giving the nod to ceftolozane with tazobactam. The drug will be marketed as Zerbaxa by the pharmaceutical company Cubist. Ceftolozane is a novel cephalosporin, combined with the existing β-lactamase inhibitor tazobactam in the new product. Zerbaxa has broad activity against gram-negative [... read more]
The post FDA approves ceftolozane/tazobactam (Zerbaxa); 4th new antibiotic in 2014 appeared first on PulmCCM.